P2X3 Receptor Antagonists for Pain Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective and specific agonists and antagonists for P2X receptor subtypes, particularly for P2X3 receptors, which are crucial for managing pain and other diseases related to pain, inflammatory pain, and tissue injury, due to susceptibility to enzymatic degradation and the complexity of evaluating individual receptor roles.
Innovation Solution
Development of novel P2X3 receptor antagonists with specific structural formulas, including benzimidazolyl, benzimidazolone, imidazopyridyl, and benzotriazolyl derivatives, which act as modulators to block pain transmission and treat associated diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current methods are used to evaluate P2X receptor roles, then research can be conducted, but the evaluation is complicated and lacks specificity for individual receptor subtypes
Solution Approach 1:
The patent introduces specific antagonist compounds (e.g., NF 110, NF 146, NF 219) as intermediary tools to selectively block P2X3 receptors. These compounds serve as mediators that enable precise evaluation of P2X3 receptor function without the complexity of evaluating all P2X subtypes simultaneously, allowing researchers to isolate and study individual receptor roles.
Solution Approach 2:
The patent segments the broad P2X receptor family into specific subtype evaluations by using selective antagonists for P2X3 receptors. This segmentation allows independent study of P2X3 function separate from other P2X subtypes, simplifying the research approach while improving measurement precision for individual receptor roles.
2Reliability
If ATP is used to activate P2X3 receptors, then pain transmission can be studied, but ATP is susceptible to enzymatic degradation reducing effectiveness
Solution Approach 1:
The patent employs ATP as a short-lived agonist that can be continuously applied in experimental settings. Although ATP is susceptible to enzymatic degradation, its short duration of action allows for repeated applications and continuous stimulation protocols, making it a practical choice for studying pain transmission mechanisms despite its limited stability.
Solution Approach 2:
The patent uses selective P2X3 antagonists (NF 110, NF 146, NF 219) to block receptor activity following ATP application. This preliminary anti-action allows researchers to confirm P2X3-mediated effects by reversing ATP-induced responses, thereby validating the specificity of ATP's action on P2X3 receptors despite ATP's susceptibility to degradation.
Data Source
AI summary
The subject invention relates to novel P2X3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or tissue injury pain that can be treated using a P2X3 receptor subunit modulator.